Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesDevelopment and Initial Validation of a Novel System to Assess Ichthyosis Severity
Sun Q, Asch S, Bayart C, Bayliss SJ, Benjamin L, Bruckner A, DiGiovanna JJ, Fleckman P, Funk T, Lucky A, Nelson CA, Newell B, Polcari I, Teng J, Williams ML, Gan G, Deng Y, Paller AS, Choate KA. Development and Initial Validation of a Novel System to Assess Ichthyosis Severity. JAMA Dermatology 2022, 158: 359-365. PMID: 35171201, PMCID: PMC8851366, DOI: 10.1001/jamadermatol.2021.5917.Peer-Reviewed Original ResearchConceptsIchthyosis severityIntraclass correlation coefficientIntrarater reliabilityCare of patientsQuantifying treatment outcomesPatient advocacy groupsMost body sitesGood interrater reliabilityReferral centerDisease burdenClinical trialsTreatment outcomesErythema scoreMAIN OUTCOMEQualitative studyScoring systemBody sitesSeverityInterrater reliabilityUser-friendly instrumentErythemaPhotographs of participantsCohortDermatologistsEntire body